

Supporting HTA/Payer decision-making: Spotlight on national health data initiatives

Spotlight on Finland, France and Spain

Tuesday, 3 May 2022 | 15.00-16.30 CET

SPEAKER BIOGRAPHIES

Karen Facey (co-moderator)

Evidence Based Health Policy Consultant to RWE4Decisions Secretariat



Dr. Karen Facey worked as a senior statistician in the pharmaceutical sector and UK medicines regulation, before becoming the founding Chief Executive of the first national HTA agency in Scotland. Since 2003, Dr Facey has been an independent consultant on health policy, HTA and patient involvement. She has served as Non-Executive Director on Scottish health boards and led research at the University of Edinburgh on appraisal of rare disease treatments in the IMPACT HTA project. She is passionate about holistic HTA to determine value and use of health service data to improve patient care. Dr Facey has facilitated the development of the RWE4Decisions multi-stakeholder initiative and is the lead author of the paper on 'Real-World Evidence to Support Payer/HTA Decisions about Highly Innovative Technologies in the EU – Actions for Stakeholders', commissioned by the Belgian payer INAMI-RIZIV.

Matti Aapro, M.D. (co-moderator)

Director of the Genolier Cancer Center, Genolier, Switzerland



Matti Aapro is member of the Board of Directors of the Genolier Cancer Center, Genolier, Switzerland and Immediate Past-President of the European Cancer Organisation. Dr. Aapro is Executive Board member of All.Can and President of Sharing Progress in Cancer Care (SPCC), both not-for-profit associations. He serves the International Society for Geriatric Oncology (SIOG) as Executive Board Member. He is past-President of the Multinational Association for Supportive Care in Cancer (MASCC). He continues to collaborate with the European School of Oncology (ESO) where he now serves on the Scientific Advisory Board. He is member of the Board of the French-speaking Society for Supportive Care (AFSOS), as well as Advisor to the Japanese Association for Supportive Care in Cancer (JASCC). He has been member of the Board of the European Organization for Research and Treatment of Cancer (EORTC) and of the Board of the European Society of Medical Oncology (ESMO).

Jo De Cock

This webinar is hosted by the Belgian National Institute for Health and Disability Insurance (INAMI-RIZIV). The RWE4Decisions Secretariat, provided by FIPRA, supports INAMI with the coordination and is financially supported by the European Confederation of Pharmaceutical Entrepreneurs (EUCOPE), AstraZeneca, Bayer, Boehringer Ingelheim, Novartis and Roche.

CEO, INAMI - RIZIV



Jo De Cock has been CEO of the Belgian National Institute of Health and Disability Insurance (INAMI- RIZIV) since 1995. Prior to this, he was a Deputy Director and Counsellor for social affairs in the office of the Belgian Prime Minister (1985-1993) and later filled the position of adjunct general administrator of the National Social Security Office (1993-1995). Under Jo De Cock's thought leadership as CEO, INAMI-RIZIV conveyed a series of roundtables bringing together different stakeholders to consider the use of real-world evidence to ensure short term affordability, long-term sustainability and patient access in 2018 and 2019. This resulted in several papers including on '[The use of real world data throughout an innovative medicine's lifecycle](#)', '[Outcomes based pricing and reimbursement of innovative medicines with budgetary limitations](#)' and '[TRUST4RD: Tool for Reducing Uncertainties in the evidence generation for specialised Treatments for Rare Diseases](#)' (published in Orphanet). Since its creation in 2019, Jo De Cock is closely involved in the [International Horizon Scanning Initiative](#) (IHSI), an independent entity legally registered at RIZIV/INAMI and a spin-off of the BeNeLuxA initiative which aims to provide data to payer organisations and decision-makers to drive better medicinal products pricing.

Piia Rannanheimo

Pharmaeconomist, Finnish Medicines Agency (Fimea)



Piia Rannanheimo is a pharmacoconomist at the Finnish Medicines Agency (Fimea). She joined Fimea's HTA-team in 2010. With a background in Pharmaceutical Sciences, Rannanheimo has contributed to numerous national, Nordic and European HTAs and worked as a visiting researcher at CADTH and Center for Health Economics at University of York. She also serves as an expert for the Council for Choices in Health Care in Finland. She's also been a member in several working groups led by the Ministry of Social Affairs and Health in Finland, covering rational use of medicines, HTA, RWD and data management. Currently, she's working as a project manager in a work that that aim's in the establishment of national medicinal product data repository.

Dr Jean-Pierre Thierry

Senior Medical Advisor at France Assos Santé and Scientific Committee Member as Patients Associations representative at HAS



Dr Jean-Pierre Thierry is Senior Medical Advisor at France Assos Santé, the National Union of Health System Associations in France representing the interests of patients and health system users. He is also a Scientific Committee Member at the French National Authority for Health (HAS), the independent public scientific authority contributing to the regulation of the French healthcare system. A medical doctor by training, Jean-Pierre held various positions in public and private healthcare-related organisations for over 25 years, focusing on helping foster innovation. He was also an independent expert for the European Commission for the European research and innovation funding programme Horizon 2020.

Carlos Martín Saborido

Advisory member General Directorate of the Common NHS Services Portfolio and Pharmacy, Spanish Ministry of Health



Carlos Martín Saborido is a Health Economist working on HTA evaluations since 2007, first in Spain HTA Agencies, then in the UK for NICE, and then later on at the Joint Research Centre (European Commission) and now at the Spanish Ministry of Health as an Assessor in the area of Health Economics and RWE to support decisions. His work focuses on giving advice for the economic evaluation of health technologies and the analysis of data from the VALTERMED RWE database. Since 2019, Saborido has been working on the collection of data on use of drugs to generate evidence to support funding and reimbursement decisions.